Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Designated Drug Use Investigation (Long-Term Administration) of Zetia [ezetimibe] 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy.

Trial Profile

Designated Drug Use Investigation (Long-Term Administration) of Zetia [ezetimibe] 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezetimibe (Primary) ; Antihyperlipidaemics
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type II; Sitosterolaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Organon; Schering-Plough

Most Recent Events

  • 29 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 19 Aug 2009 Planned end date changed from 1 Jun 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
  • 12 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top